




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>4</sup> : <b>A61B 8/12</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 89/12425</b> (43) International Publication Date: 28 December 1989 (28.12.89)</p>
<p>(21) International Application Number: PCT/US89/01574 (22) International Filing Date: 13 April 1989 (13.04.89) (30) Priority data: 210,718 23 June 1988 (23.06.88) US (71) Applicant: APPLIED BIOMETRICS, INC. [US/US]; 14873 DeVeau Place, Minnetonka, MN 55345 (US). (72) Inventor: WEBER, Roland, E. ; 40 Clay Cliffe Drive, Tonka Bay, MN 55332 (US). (74) Agents: VIDAS, Robert, O. et al.; Vidas &amp; Arrett, 45 South 7th Street, Suite 1904, Minneapolis, MN 55402 (US). (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p>		<p><b>Published</b> <i>With international search report.</i></p>

(54) Title: ENDOTRACHEAL TUBE WITH ASYMMETRIC BALLOON



## (57) Abstract

Aortic and pulmonary blood flow is measured by an apparatus (10) which comprises a tracheal flexible tubing (11) having an ultrasound transducer assembly (21) mounted at one end. A single inflatable asymmetric balloon cuff member (29) is mounted on the tube (11) in proximity to and above the transducer assembly (21) and extends around the entire periphery of the tube such that when inflated the balloon sealingly engages the tracheal wall to positively locate the tube while urging the transducer assembly into contact with the trachea. The asymmetric balloon cuff is conveniently formed in a mold prepared by angularly sectioning the conical portion of a pair of funnel shaped mold forms at equal angles relative to the central axis and then joining the two forms at the section plane to form the balloon cuff mold form.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IT	Italy	RO	Romania
BJ	Benin	JP	Japan	SD	Sudan
BR	Brazil	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LJ	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LJ	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

## ENDOTRACHEAL TUBE WITH ASYMMETRIC BALLOON

### Background of Invention

#### Field of Invention

Measurement of cardiac output is crucial in the care of critically ill patients such as patients with multiple trauma, patients in overwhelming sepsis, and patients with acute myocardial infarction. In the case of patients with acute myocardial infarction, there is a worsening prognosis with decrease in cardiac output. Knowledge of the cardiac output provides information useful in determining the clinical state of a given patient and in rationally planning therapy for the patient. Such information is not contained in the usually measured vital signs. For example, a low mean arterial pressure with elevated pulse does not adequately distinguish between cardiogenic and septic shock, the treatments for which are quite different. Consequently, a method that distinguishes between cardiogenic and septic shock would be important in planning appropriate therapy. The measurement of cardiac output, in this case, would provide valuable information that would allow an appropriate diagnosis to be made.

#### Prior Art

The importance of knowing cardiac output has led to many methods for its determination. The most commonly used method in widespread clinical use is thermodilution. In the thermodilution method a catheter is placed into the central venous circulation, usually by percutaneous entry into the internal jugular or subclavian vein. A balloon at the end of the catheter is inflated, and the normal flow of blood is employed to direct the tip of the catheter into the pulmonary artery. Measurement of cardiac output is made by observing the dissipation of a temperature pulse, usually a bolus of iced sterile water or saline solution. As is evident, the method cannot be used without invasion of the vascular tree. Indeed, the catheter is threaded through the heart and the heart valves. Flow direction is not entirely reliable. In certain patients access to the pulmonary artery is impossible. During placement of the

1 catheter cardiac arrhythmias are not uncommon. Other complications  
2 include sepsis, thrombosis of the central veins, emboli, and fatal  
3 rupture of the pulmonary artery. Other disadvantages of the tech-  
4 nique include lack of continuous information about the cardiac out-  
5 put and chance location of the catheter, such as in an unfavorable  
6 pulmonary artery branch, with erroneous values for the cardiac out-  
7 put. Analysis of the error inherent in the measurement of blood flow  
8 by thermodilution has revealed a standard deviation of 20-30%.

9 Measurement of cardiac output has also been done by the  
10 indocyanine green dye technique, which suffers from several disad-  
11 vantages. The technique is cumbersome, it requires the placement of  
12 an arterial catheter, is not accurate at low levels of cardiac out-  
13 put and is difficult to use for repeated measurements in the same  
14 patient. Complications include catheter site hematoma, sepsis from  
15 the catheter, thromboses of the artery containing the indwelling  
16 catheter, and pseudoaneurysm formation at the site of arterial punc-  
17 ture.

18 The Fick method is based on the measurement of oxygen  
19 consumption. It is best used in awake, alert, stable patients not  
20 requiring respiratory support on a ventilator. The method requires  
21 invasion of the pulmonary artery in order to obtain samples of mixed  
22 venous blood for determination of the oxygen content. Like the in-  
23 docyanine green dye technique, an arterial catheter must be placed  
24 for sampling of arterial blood for oxygen content with the disad-  
25 vantages mentioned above.

26 Transcutaneous ultrasound has also been used.  
27 Ultrasound transducers are placed externally on the body at the  
28 suprasternal notch. Under the most sanguine circumstances, at least  
29 10% of patients cannot have their cardiac outputs measured in this  
30 way. Many difficulties with this approach have been reported:  
31 repeated measurements may lead to varying location of the sample  
32 volume that is scanned, there are changes in the angle of intersec-  
33 tion of the ultrasound beam with the axis of the vessel, capability  
34 for continuous measurement of the cardiac output is not available,  
35 and other major thoracic vessels may interfere with the Doppler

1 ultrasound signals. Further, the method is not feasible in many im-  
2 portant clinical settings in which the patients are not cooperative  
3 or are in the operating room, where the suprasternal notch may not  
4 be accessible.

5           Because of these difficulties, an implantable, removable  
6 Doppler ultrasound device for measurement of the cardiac output has  
7 been developed for direct attachment to the aorta. The device re-  
8 quires a major, operative, invasive intervention, such as splitting  
9 the sternum or removal of a rib to enter the chest cavity, for  
10 placement of the device directly on the wall of the aorta. Removal  
11 of the device also requires surgical intervention. If the device  
12 were to be lost in a major body cavity, a major surgical procedure  
13 would be required.

14           Measurement of cardiac output by continuous or single  
15 breath, gas-washout has been attempted, but is not used in standard  
16 clinical medicine. Such methods require many approximations of lung  
17 function in modeling the system. Time consuming numerical analysis  
18 is required. In one study, measurement of cardiac output in anes-  
19 thetized patients using argon and freon during passive rebreathing  
20 was shown to provide lower cardiac outputs than a simultaneously  
21 performed Fick determination. The authors concluded that the method  
22 caused significant disturbances of hemodynamics and was therefore  
23 not suitable for widespread use.

24           Indirect measurements include the pulse, blood pressure,  
25 and urine output, but these measurements are not specific for car-  
26 diac output. For example, in the presence of acute renal failure,  
27 urine output cannot be correlated with perfusion of major organs.

28           In the patent art, Tickner, U.S. Patent No. 4,316,391  
29 discloses an ultrasound technique for measuring blood flow rate.  
30 Colley et al., U.S. Patent No. 4,354,501, discloses an ultrasound  
31 technique for detecting air emboli in blood vessels. Numerous  
32 patents disclose catheters or probes, including Calinog, U.S. Patent  
33 No. 3,734,094, Wall, U.S. Patent No. 3,951,136, Mylrea et al., U.S.

34  
35  
36

1 Patent No. Re. 31,377, Perlín, U.S. Patent Nos. 4,304,239; 4,304,240  
2 and 4,349,031, Colley et al., U.S. Patent No. 4,354,501 and Furler,  
3 U.S. Patent No. 4,369,794.

4 U.S. Patent No. 4,331,156 discloses an esophageal car-  
5 diac pulse probe which utilizes a closed end lumen with a pressure  
6 transmitting fluid therein to transmit sounds from the heart and  
7 lungs to an external transducer.

8 In U.S. 4,671,295 and 4,722,347 there is described a  
9 method and apparatus for measuring cardiac output which comprises  
10 placing an ultrasound transducer in great proximity to the ascending  
11 aorta of the heart of the mammal by passing a probe carrying the  
12 transducer into the trachea and transmitting ultrasound waves from  
13 the transducer toward the path of flow of blood in the ascending  
14 aorta. The probe can be passed through the nasal or oral cavity,  
15 past the epiglottis into the trachea or, in the case of patients who  
16 have had a tracheostomy, directly into the trachea through the sur-  
17 gical opening. The reflected ultrasound waves are received by the  
18 transducer and the average Doppler frequency difference between the  
19 transmitted waves and the reflected waves is measured. The cross-  
20 sectional size or area of the ascending aorta at the point of  
21 ultrasound reflection is calculated and the volumetric blood flow  
22 rate is determined from such measurements. The method and apparatus  
23 for measuring cardiac output described in U.S. Patents 4,671,295 and  
24 4,722,347 provides for the determination of the cardiac output in a  
25 way that is accurate, noninvasive, continuous, inexpensive and  
26 suitable for use in those patients whose cardiac output measurement  
27 is most critical.

#### 28 Summary of the Invention

29 The present invention comprises an improvement in the  
30 apparatus of U.S. 4,671,295 and 4,722,347. In one embodiment the  
31 invention comprises an improved tracheal probe for use in determin-  
32 ing blood flow in a major discharge artery, including the pulmonary  
33 artery and the aorta, of a mammalian heart, which comprises:

34  
35  
36

1 a. a flexible tube having a length sufficient to ex-  
2 tend from the oral or nasal cavity of the mammal or from the surgi-  
3 cal tracheal opening through the trachea to the bifurcation thereof,

4 b. an ultrasound transducer assembly mounted to the  
5 tube in proximity to the distal end thereof, and

6 c. means mounted on the tube for urging the  
7 transducer into contact with the inner wall of the trachea, the im-  
8 provement comprising that said urging means comprises a single asym-  
9 metric inflatable balloon cuff member in proximity to and above the  
10 transducer assembly and extending around the entire periphery of the  
11 tube, said single asymmetric balloon being mounted on the tube such  
12 that when inflated the balloon sealingly engages the tracheal wall  
13 while urging the transducer into contact with the inner wall of the  
14 trachea.

15 In another aspect of the invention the inventive balloon  
16 cuff may be used with any device, mounted on a catheter or flexible  
17 tube which is inserted into a mammalian body passageway and threaded  
18 through the passageway to a point in the body where it is desired  
19 that the device mounted on the catheter or flexible tube contact the  
20 side wall of the body passageway.

21 A still further aspect of the invention comprises a  
22 method for manufacturing the balloon cuff mold by angularly section-  
23 ing the conical portion of a pair of funnel shaped mold forms at  
24 equal angles relative to the central axis thereof, rotating one of  
25 the sectioned funnel forms 180° about the axis and then joining the  
26 two forms at the section plane to produce the balloon cuff mold  
27 form.

28 The asymmetric balloon mold and the balloon molded  
29 therefrom are further aspects of the invention.

### 30 Brief Description of the Drawings

31 FIG. 1 is a front-to-back vertical sectional view of the  
32 upper portion of the human body showing the oral cavity and the  
33 pathway through the trachea to the bifurcation thereof. The heart  
34 is shown in lateral or side view. The tracheal probe of the inven-

35  
36

1 tion is shown in position in the trachea with the transducer as-  
2 ssembly contacting the tracheal wall in proximity to the ascending  
3 aorta.

4 FIG. 2 is a front view of the ascending aorta, the  
5 trachea, including the bifurcation thereof, and the esophagus and  
6 shows the close relationship between the tracheal and the ascending  
7 aorta.

8 FIG. 3 is a horizontal sectional view of the trunk of a  
9 human taken at the level of the tracheal bifurcation and shows the  
10 close relationship between the trachea and the ascending and descen-  
11 ding aorta and the pulmonary arteries.

12 FIG. 4 is a perspective view from the left side of the  
13 tracheal probe of the present invention with the balloon inflated.

14 FIG. 5 is a front view of the preferred balloon cuff of  
15 the invention.

16 FIG. 6 is a left side view of the preferred balloon cuff  
17 of the invention.

#### 18 Description of Preferred Embodiment

19 Reference is made to the disclosure of U.S. Patents  
20 4,671,295 and 4,722,347 for a detailed description of the theory and  
21 operation of the tracheal probe and for modifications, not relevant  
22 to the present invention, which may be employed. The present dis-  
23 closure should be considered in conjunction with those two patents  
24 to the extent necessary to fully understand the invention.

25 The apparatus of the preferred embodiment consists of a  
26 probe with a piezoelectric transducer mounted at one end and  
27 electrical conductors extending the length of the probe for connec-  
28 tion to conventional directional pulsed or continuous wave Doppler  
29 ultrasound hardware, such as that described by Hartley et al. in the  
30 Journal of Applied Physiology, October 1974, and by Keagy et al. in  
31 the Journal of Ultrasound Medicine, August 1983. Modifications to  
32 the signal output can be made to display blood flow volume rate,  
33 aorta or other vessel diameter, blood velocity and other selected  
34 displays.

35

36



1           The probe 10 is shown in Figures 1 and 6. Probe 10 con-  
2           sists of flexible plastic tubing 11. The length must be sufficient  
3           to extend from outside the body to the vicinity of the heart through  
4           the trachea, entering either through the nasal or oral cavity or  
5           through a surgical opening in the case of patients who have had a  
6           tracheotomy. The particular probe shown in Fig. 1 is adapted for  
7           oral insertion.

8           Near the distal end of the probe a transducer assembly  
9           21, suitably comprising one or more piezoelectric transducers and  
10          associated lenses, is mounted on the exterior of tubing 11.  
11          Transducer assembly 21 is used to collect Doppler data for  
12          velocity calculation and to collect data for calculation of the  
13          diameter of the artery at the point of velocity measurement.  
14          Electrical conductors 24, extend the length of tube 11 for connec-  
15          tion of transducer assembly 21 to conventional Doppler ultrasound  
16          hardware.

17          An acoustical gel, such as Aquasonic 100, a trademark of  
18          and available from Park Laboratories, Orange, New Jersey, may be  
19          placed on the surface of the transducer assembly to fill in the  
20          small, irregular space or spaces between the transducer lens and the  
21          trachea that remain because of the irregularly shaped and relatively  
22          non-deformable cartilaginous inner surface of the trachea when the  
23          lens engages the trachea. Alternatively, a generous application of  
24          a conventional lubricant, such as a anesthetic lubricant, commonly  
25          used when inserting a tracheal tube can be relied upon to provide  
26          whatever gap filling is necessary.

27          An understanding of the use of the present invention re-  
28          quires some understanding of mammalian anatomy and in particular an  
29          understanding of the human anatomy, which is shown in pertinent por-  
30          tion in Figures 1, 2 and 3. The apparatus is used by placing the  
31          ultrasound transducer assembly 21 in great proximity to the arterial  
32          vessel in which blood flow is to be measured, most typically the as-  
33          cending aorta of a human, without surgery or other invasive tech-  
34  
35  
36

1 niques. The method relies on the anatomical discovery or fact that  
2 the ascending aorta is located adjacent the trachea just above the  
3 bifurcation thereof, and that a transducer placed in the trachea can  
4 be directed toward the ascending aorta and accurate blood flow  
5 measurements made without significant interference. With reference  
6 to Figures 1, 2 and 3, access to the trachea, T, of a human, H, can  
7 be had in accordance with standard medical practice through the  
8 nasal cavity, N, or the oral cavity, O, past the epiglottis, E, and  
9 into the trachea, T. Access can also be had through a surgical open-  
10 ing at the suprasternal notch, S, in the case of patients who have  
11 had a tracheotomy. The ascending aorta, A, and the pulmonary artery,  
12 PA, are located in great proximity to the trachea, T, just above the  
13 bifurcation, as best seen in Figures 2 and 3.

14 Consequently, a transducer or transducers placed in the  
15 trachea as shown in Figure 1 can be directed to transmit and receive  
16 ultrasound waves through the wall of the trachea and through the  
17 wall of the ascending aorta or the pulmonary artery to be reflected  
18 by the blood flowing in the selected artery and, due to the movement  
19 of the blood, cause a Doppler shift in the frequency of the  
20 reflected waves as compared to the frequency of the transmitted  
21 waves. The ultrasound waves are also reflected by the near and far  
22 walls of the artery and such reflection can be used for diameter  
23 measurement of the artery.

24 Means is provided to positively locate probe 10 in  
25 trachea, T, and to urge transducer assembly 21 into intimate contact  
26 with the inner wall of the trachea.

27 The disclosed device of U.S. 4,671,295 and 4,722,347  
28 utilizes a pair of inflatable balloons to properly position the  
29 transducer assembly 21 against the wall of the trachea in proximity  
30 to the ascending aorta. One such balloon is a donut shaped cuff  
31 which positions the probe in the center of the trachea and seals the  
32 trachea. A second balloon, located on the back side of the probe  
33 behind the transducer assembly, is inflated to urge the transducer  
34 assembly against the tracheal wall. This is a complicated construc-  
35 tion and it is an object of the invention to simplify the construc-  
36

1 tion by utilizing a single balloon cuff, asymmetrically disposed  
2 about the axis of the tube 11 when viewed from the side, to simul-  
3 taneously seal the trachea, securely position probe 10 in the  
4 trachea and urge the transducer assembly 21 against the tracheal  
5 wall in proximity to the selected artery.

6 The asymmetric balloon is designated by the numeral 29  
7 and is shown in detail in figures 4-6. The balloon is made of con-  
8 ventional materials. Suitably it is dip or blow molded. The mold  
9 is formed by sectioning a pair of cones, suitably funnel shaped  
10 cones, at an acute angle relative to the central axis thereof,  
11 rotating one of the cones 180° relative to the other and joining the  
12 two cones along the section line. The resulting mold form has the  
13 shape of the balloon, shown in figures 4 and 5. The balloon has a  
14 pair of sleeves 30 formed by the funnel shaft for mating the cuff to  
15 tubing 11 over an opening to an inflation lumen 31 which runs along  
16 tube 11. Circumferential line 32 defines the mating edges of the  
17 two cones. The angle of the conical section relative to the central  
18 axis of the cone is designated  $\theta$  in figure 6. The angle of the  
19 conical surfaces relative to the central axis of the cone is desig-  
20 nated  $\phi$  in figure 5. Neither angle  $\theta$  nor angle  $\phi$  are critical and  
21 the selection of angle will generally be determined by the  
22 desirability of complying with industry standards regarding the  
23 overall dimensions of trachea sealing balloons. Without limitation,  
24 however, angle  $\theta$  may suitably be in the range of 50°-75°, preferably  
25 60°-65° and angle  $\phi$  may suitably be in the range of 10°-30°,  
26 preferably about 15°-20°.

27 As shown in figure 5, the preferred balloon when viewed  
28 from the front is symmetric about the plane the passing through axis  
29 line 40 and perpendicular to the page. Preferably when the balloon  
30 is mounted on tube 11 this line of symmetry is aligned with the  
31 plane which passes through the central axis of tube 11 and the cen-  
32 ter of transducer assembly 21. However, the two planes may be off-  
33 set slightly without departing from the invention hereof.

34  
35  
36

1           The asymmetry of the balloon when viewed from the side  
2 is such that when inflated the balloon has a bulge 42 on the back  
3 side thereof on the portion of the cuff closest to the transducer  
4 and a second bulge 43 on the front side of the probe of the portion  
5 of the cuff furthest from the transducer.

6           The structure of balloon 29 allows a single balloon to  
7 accomplish the functions of the dual balloon system disclosed in  
8 U.S. Patents 4,671,295 and 4,722,347. The use of mated angularly  
9 sectioned cones to provide a mold configuration conferring the  
10 desired asymmetry in the balloon allows the mold to be prepared very  
11 inexpensively. These features provide significant advantages over  
12 the dual balloon system of U.S. Patents 4,671,295 and 4,722,347.

13           In use probe 10 is placed to locate transducer assembly  
14 21 in the trachea, T, pointing toward the selected artery, suitably  
15 as the ascending aorta. The position of probe 10 and transducer as-  
16 sembly 21 can be adjusted until the maximum Doppler shift is ob-  
17 tained and the position can also be checked or confirmed by X-rays  
18 to insure placement for optimum data collection. In general,  
19 transducer assembly 21 should be located just above the tracheal  
20 bifurcation and directed toward the selected artery.

21           For ventilation purposes it is necessary to seal the  
22 trachea. It is also important that the transducer assembly 21 be  
23 held in position so that it is not moving about within the trachea  
24 while measurements of cardiac output are being taken. Use of a  
25 traditional symmetric balloon will force the distal end of the probe  
26 away from the wall of the trachea and toward the center thereof,  
27 thus requiring a second means for urging the transducer assembly  
28 against the tracheal wall. The asymmetric balloon 29, however,  
29 complements the natural curvature of tube 10, shown in Fig. 4, so  
30 that it effectively seals the trachea and holds the tube in place  
31 while simultaneously urging the transducer assembly 21 into acoustic  
32 contact with the tracheal wall. Inflation of asymmetric balloon 29  
33 is accomplished with using conventional procedures for inflating an  
34 endotracheal tube balloon.

35  
36

1           In other respects the endotracheal tube 10 is con-  
2     structed in accordance with recognized standards for construction of  
3     endotracheal tubes. In particular, the distal end suitably is  
4     provided with a standard bevel opening 33 and oppositely directed  
5     Murphy eye 34 manufactured in accordance with ANSI standards.

6           After proper placement of probe 10 and connection with  
7     the electrical hardware, ultrasound signals are generated and the  
8     Doppler shift is measured for velocity calculation and data for cal-  
9     culating the diameter of the artery is also collected. These data  
10    are used to determine the volumetric rate of blood flow as set forth  
11    in detail in US 4,671,295 and 4,722,347.

12           A large number of patients who require continuous  
13    measurement of cardiac output have significant associated clinical  
14    problems. Often such patients have multiple systems organ failure,  
15    overwhelming sepsis, significant trauma to many major organ systems,  
16    decompensated congestive heart failure, or major myocardial infarc-  
17    tion. Such patients often have an endotracheal tube in place because  
18    of such problems. For example, in patients having a major surgical  
19    procedure, use of general anesthesia requires the presence of an en-  
20    dotracheal tube for the maintenance of the patient's airway. In the  
21    case of patients having open heart surgery, an endotracheal tube is  
22    often in place for the night following surgery. Patients suffering  
23    major trauma are routinely intubated following significant thoracic  
24    trauma, significant head injury, or multiple abdominal injuries.  
25    Patients in multiple systems organ failure, septic shock, or hemor-  
26    rhagic shock have endotracheal tubes in place to assist ventilation  
27    during acute decompensation and in the immediate resuscitation  
28    phase. Patients with significant burn injuries frequently require  
29    endotracheal intubation during initial resuscitation, for transpor-  
30    tation to a burn center, and for thermal injury to the respiratory  
31    system. Patients with decompensated congestive heart failure leading  
32    to pulmonary decompensation with pulmonary accumulation of fluid re-  
33    quire endotracheal intubation. Such patients may have underlying  
34    myocardial infarction, cardiomyopathy, cardiac valvular disease, or  
35    chronic congestive heart failure. In many of these examples, stabi-  
36

1 lization of the cardiovascular system is a prerequisite for removal  
2 of the tracheal tube. Consequently, use of an endotracheal probe in  
3 accordance with the present invention represents no further invasion  
4 of any body cavity. Thus, in the case of patients already having a  
5 tracheal tube in place, as well as in patients in which no tracheal  
6 tube has been previously placed for other reasons, the present in-  
7 vention provides for measurement of cardiac output at optimum loca-  
8 tions without major surgical procedure or invasion of a closed body  
9 system. No invasion of a major body cavity, not routinely in com-  
10 munication with the external environment, is required. No major or  
11 minor surgical procedure is required. No indwelling foreign body is  
12 necessary in the vascular system, a major body cavity, or in a major  
13 organ. No dye or radioactive substance is necessary for the measure-  
14 ment to be performed, and no air emboli are introduced. Continuous  
15 monitoring is also possible.

16           While the foregoing description of applicants' invention  
17 is directed to measurement of cardiac output in the ascending aorta,  
18 measurement of blood flow in the descending aorta, the right pulmo-  
19 nary artery and the left pulmonary artery can also be made with the  
20 applicants' apparatus. Moreover, the inventive balloon cuff can  
21 also be usefully employed with other devices located on catheters or  
22 other flexible tubes and inserted through a tubular body passageway  
23 to a point where it is desired that the device contact the wall of  
24 the passageway to effectively operate the device. For instance, a  
25 balloon cuff of the invention may be used to position the end of a  
26 laser angioplasty device of the type disclosed in U.S. 4,685,458  
27 adjacent to a plaque deposit in an artery.

28

29

30

31

32

33

34

35

36

1

2

## CLAIMS

3

4

I claim:

5

6

1. A tracheal probe for use in determining blood flow rate in a major discharge artery, including the pulmonary artery and the aorta of a mammalian heart comprising:

7

8

9

10

a. a flexible tube having a longitudinal axis and a length sufficient to extend from the oral or nasal cavity of the mammal or from a surgical tracheal opening through the trachea to the bifurcation thereof,

11

12

13

b. an ultrasound transducer assembly mounted to the tube in proximity to the distal end thereof and,

14

15

16

17

18

19

20

21

22

23

24

25

26

2. The tracheal probe of claim 1 wherein the distal end of the tube is open to provide for ventilation of the mammal through the tube.

27

28

29

30

31

32

33

34

35

36

3. The probe of claim 1 wherein the said cuff member when inflated is generally symmetric about a first plane which passes through the axis of the tube and through said transducer and said cuff member is asymmetric about a second plane generally perpendicular to said first plane, said second plane defining front and back sides of the probe, the side bearing the transducer assembly

1 being the front side, the asymmetry of the cuff member causing the  
2 portion of the cuff closest to the transducer assembly to be en-  
3 larged on the back side of the probe relative to the front side  
4 thereof and causing the portion of the cuff member furthest from the  
5 transducer assembly to be enlarged on the front side relative to the  
6 backside of the probe.

7 4. A probe having an elongated flexible member having an  
8 axis and a device mounted thereto, whereby the device may be in-  
9 serted into a mammalian body and passed through a tubular pas-  
10 sageway in the body to a point where it is desired that the device  
11 contact the wall of said passageway to effectively operate the  
12 device, the improvement comprising that the said elongated flexible  
13 member includes an inflatable balloon cuff member asymmetric about  
14 the axis of said flexible flexible member in proximity to and  
15 proximal along said flexible member with respect to the said device  
16 extending around the entire periphery of the flexible member and  
17 means for inflating said asymmetric balloon cuff member, said bal-  
18 loon cuff member being mounted on the flexible member such that when  
19 inflated the balloon sealingly engages the wall of the passageway  
20 while urging the said device into contact with the inner wall of  
21 said passageway.

22  
23 5. A mold form for a balloon cuff, said form comprising a  
24 pair of mated angularly sectioned cones, the two cones being sec-  
25 tioned at equal acute angles relative to the central axis thereof,  
26 the cones being mated along the lines thereof with one cone rotated  
27 180° about its axis relative to the other.

28  
29 6. A mold form as in claim 4 in which each of said cone  
30 portions is derived from a conical funnel having a tubular shaft  
31 portion at the apex thereof, said shaft portions providing forms for  
32 forming a pair of sleeves on the opposite ends of the said balloon  
33 cuff.


34  
35 7. A balloon cuff formed in a mold form as in claim 5.

36




1/2


**Fig. 1**




**Fig. 2**




**Fig. 3**




**Fig. 4**



**Fig. 5**




**Fig. 6**



# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/01574

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (4): A61B 8/12 US.C1.: 128/662.06, 425/275		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
U.S.	128/662.06, 207.15, 642, 673, 713, 715, 773 604/96, 97, 98, 99, 100, 101, 102 and 103 249/58, 117, 175, 184 425/117, 175, 269, 275, 522	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>9</sup>		
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	US,A, 4,727,347 02 FEBRUARY 1988 (ABRAMS ET AL). See entire document	1-4
X	US,A, 4,700,700 (ELIACHAR) 20 OCTOBER 1987. See column 6 line 34 through column 7 line 25.	4
A	US,A, 4,671,295 (ABRAMS ET AL) 09 JUNE 1987. See entire document.	1-4
A,P	US,A, 4,794,931 (YOCK) 03 JANUARY 1989. See entire document.	1-4
A	US,A, 4,685,458 (LECKRONE) 11 AUGUST 1987. See entire document.	1-4
A	US,A, 2,328,769 (AUZIN) 07 SEPTEMBER 1943. See entire document.	5-7
A	US,A, 4,501,545 (DIVOSKY) 26 FEBRUARY 1985. See entire document.	5-7
<p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
02 July 1989	<b>18 AUG 1989</b>	
International Searching Authority	Signature of Authorized Officer	
ISA/US	 Francis J. Jaworski	

**FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET**

--	--	--

**V.  OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>**

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1.  Claim numbers \_\_\_\_\_, because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:

2.  Claim numbers \_\_\_\_\_, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>13</sup>, specifically:

3.  Claim numbers \_\_\_\_\_, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

**VI.  OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>**

This International Searching Authority found multiple inventions in this international application as follows:

Group I (claims 1-4) drawn to an Endotracheal Ultrasonic Bloodflow Sensing Probe, classified in Class 128, Subclass 622.06, and Group II (claims 5-7) drawn to a mold for an air receptacle, classified in Class 425, Subclass 275; which inventions are distinct as end-product combination and tool for the manufacture of a combination component.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. **Telephone practice.**

2.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4.  As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

**Remark on Protest**

The additional search fees were accompanied by applicant's protest.

No protest accompanied the payment of additional search fees.